secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2026-05-13T11:00:44+00:00
Accession:  0001534120-26-000032
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo reports Q1 net loss $19.6M, Phase 2 HS trial meets endpoints, $431M offering
--------------------------------------------------------------------------------

- Phase 2 LOTUS topline: HiSCR75 absolute improvement 42.2% (150mg) and 42.9% (300mg) vs placebo 25.6%; p=0.018 and 0.015.
- Q1 2026 net loss $19.6M ($0.98 loss/share) vs $13.1M prior year, driven by higher R&D costs.
- Cash $82.0M as of Mar 31, 2026; subsequent public offering raised gross $431.3M (net $405M), extending runway into 2029.
- Milestone Buyout Option: paid $2.25M for option to replace $15M milestone with $5.125M payment upon Phase 3 start.
- R&D expense $14.0M (+$4.9M YoY); G&A $6.9M (+$1.3M YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000032/0001534120-26-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000032/avtx-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001534120-26-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer